Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers

Journal of Drug Targeting

Volumn 19, Issue 9, 2011, Pages 837-845

  Geldenhuys, Werner ^a   Mbimba, Thomas ^a   Bui, Thong ^a   Harrison, Kimberly ^a   Sutariya, Vijaykumar ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Brain cancer; Brain targeted delivery; Paclitaxel; PLGA NP; Tubulin immunofluorescent

Indexed keywords

ADENOSINE TRIPHOSPHATASE; COUMARIN; GLUTATHIONE; GLYCOPROTEIN P; NANOPARTICLE; PACLITAXEL; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENZYME ANALYSIS; IN VIVO STUDY; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; SUSTAINED DRUG RELEASE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; COUMARINS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; GLIOMA; GLUTATHIONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROTUBULES; NANOPARTICLES; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; PERMEABILITY; RATS; THIAZOLES; TUBULIN;

EID: 80054697226     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.589435     Document Type: Article

References (34)

1. Begley DJ. (2004). ABC transporters and the blood-brain barrier. Curr Pharm Des, 10, 1295-1312 (Pubitemid 38559749)
2. Brandes AA, Pasetto LM, Monfardini S. (2000). New drugs in recurrent high grade gliomas. Anticancer Res, 20, 1913-1920 (Pubitemid 30636157)
3. Breedveld P, Beijnen JH, Schellens JH. (2006). Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci, 27, 17-24 (Pubitemid 43063120)
4. Carroll RT, Bhatia D, Geldenhuys W, Bhatia R, Miladore N, Bishayee A, Sutariya V. (2010). Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target, 18, 665-674
5. Das D, Lin S. (2005). Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci, 94, 1343-1353 (Pubitemid 40904197)
6. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. (2006). Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther, 5, 2767-2776 (Pubitemid 44849003)
7. Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ. (1994). Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol, 34, 465-471 (Pubitemid 24306044)
8. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. (2002). Transport of paclitaxel (Taxol) across the bloodbrain barrier in vitro and in vivo. J Clin Invest, 110, 1309-1318 (Pubitemid 35285757)
9. Gaillard PJ, Visser CC, de Boer AG. (2005). Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv, 2, 299-309 (Pubitemid 41130884)
10. Gaillard PJ. (2010). Glutathione-based drug delivery system. PCT Int. Appl. 52pp. CODEN: PIXXD2 WO 2010095940 A2 20100826
11. Gallo JM, Li S, Guo P, Reed K, Ma J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res, 63, 5114-5117 (Pubitemid 37022652)
12. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. (1999). The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol, 9, 27-33 (Pubitemid 29190408)
13. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA, 105, 2586-2591 (Pubitemid 351520557)
14. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH. (1994). Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol, 5, 951-953
15. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. (2009). Lactoferrinconjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release, 134, 55-61
16. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. (2004). Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev, 30, 415-423 (Pubitemid 38968122)
17. Koziara JM, Lockman PR, Allen DD, Mumper RJ. (2004). Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 99, 259-269 (Pubitemid 39222111)
18. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65-81 (Pubitemid 32209233)
19. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, Walter KA. (2003). Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res, 9, 3441-3447 (Pubitemid 37082742)
20. Liang HF, Chen YC, Yang TF, Chang LW, Wang AJ, Lu JM, Jan CH, Lin YF, Liu S. (2008). Glutathione based delivery system for analgesics. U.S. Pat. Appl. Publ. 18pp., Cont.-in-part of U.S. Ser. No. 303,934
21. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. (2003). Brain uptake of thiamine-coated nanoparticles. J Control Release, 93, 271-282 (Pubitemid 37485949)
22. Mu L, Feng SS. (2003). A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release, 86, 33-48 (Pubitemid 35469120)
23. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. (2007). Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release, 124, 163-171 (Pubitemid 350101886)
24. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. (1999). Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res, 16, 1836-1842 (Pubitemid 30040699)
25. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19, 1137-1143 (Pubitemid 34984997)
26. Olivier JC. (2005). Drug transport to brain with targeted nanoparticles. NeuroRx, 2, 108-119
27. Pardridge WM. (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther, 4, 1103-1113 (Pubitemid 38937552)
28. Ren T, Xu N, Cao C, Yuan W, Yu X, Chen J, Ren J. (2009). Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/ PLA-b-PEG nanoparticles. J Biomater Sci Polym Ed, 20, 1369-1380
29. Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, 373-383 (Pubitemid 41503678)
30. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1996). Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs, 7, 78-86 (Pubitemid 26059949)
31. Sun W, Xie C, Wang H, Hu Y. (2004). Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials, 25, 3065-3071 (Pubitemid 38210199)
32. Tanner PG, Holtmannspotter M, Tonn JC, Goldbrunner R. (2007). Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery, 61, E880-2; discussion E882 (Pubitemid 350073343)
33. Wang AJ, Jian CH, Li SD, Lin YF, Liu S. (2007). Glutathione based delivery system. U.S. Pat. Appl. Publ. 13pp. CODEN: USXXCO US 2007141133 A1 20070621 CAN 147:102147 AN 2007:672399
34. Xie J, Lei C, Hu Y, Gay GK, Bin Jamali NH, Wang CH. (2010). Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. Curr Pharm Des, 16, 2331-2340